Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumor activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers.
After a huge IPO and acquisition, Zymergen caps off bankruptcy with $30M SEC penalty
The rise and fall of the short-lived biotech Zymergen has ended with a $30 million penalty from the SEC. Zymergen’s rise began in April 2021
September 14, 2024